• Else (BABY) has received Institutional Review Board (IRB) approval for its infant growth clinical study protocol
  • This is a key step toward the U.S. launch of Else’s new plant-based infant formula, which will serve as an alternative to dairy and soy-based products
  • CEO Hamutal Yitzhak spoke with Coreena Robertson about the news
  • Else is developing innovative, clean and plant-based food and nutrition products for infants, toddlers, children and adults
  • Else Nutrition (BABY) is up by 2.99 per cent trading at $0.69 per share

Else Nutrition (BABY) has received IRB approval for its infant growth clinical study protocol.

The clinical study will provide vital insights into the formula’s effectiveness and safety for infants.

This is a critical step in the company’s plan to launch a new plant-based infant formula in the U.S. as an alternative to dairy and soy-based products.

CEO Hamutal Yitzhak spoke with Coreena Robertson about the news.

Else is developing innovative, clean and plant-based food and nutrition products for infants, toddlers, children and adults.

Else Nutrition (BABY) is up by 2.99 per cent trading at $0.69 per share as of 9:44 am EST.


More From The Market Online

Lassonde to consume U.S.-based Summer Garden Food for $235 million

Agri-food stock Lassonde Industries Inc. (TSX:LAS.A) signs a deal to acquire Summer Garden Food Manufacturing for $235 million.

NVIDIA becomes world’s most valuable company amid AI boom

NVIDIA Corp. (NDAQ:NVDA; NEO:NVDA) has risen to become the world’s most valuable company, surpassing Microsoft (NDAQ:MSFT).

From robotic limbs to new highs, NVIDIA stock is on a roll

NVIDIA Corp. (NDAQ:NVDA; NEO:NVDA) opens Tuesday trading on a positive note, showing a significant upward trend.

ARway integrates tech with Apple’s new AI for Vision Pro

Arway.ai (CSE:ARWY) integrates Apple’s (NDAQ:AAPL) new enterprise APIs with its augmented reality solutions.